Measles, Mumps, Rubella Vaccine Market Size, Share and Trends 2025 to 2034

Revenue, 2024

USD 1.86 Bn

Forecast Year, 2034

USD 4.21 Bn

CAGR, 2025 - 2034

8.51%

Report Coverage

Global

What is Measles, Mumps, Rubella Vaccine Market Size?

The global measles, mumps, rubella vaccine market size accounted for USD 2.02 billion in 2025 and is predicted to increase from USD 2.19 billion in 2026 to approximately USD 4.21 billion by 2034, expanding at a CAGR of 8.51% from 2025 to 2034. The rising efforts of public health agencies to increase the awareness about benefits of vaccination in communities across the world is likely to boost the growth of the market during the forecast period.

Market Highlights

• North America dominated the market with the largest share of 41% in 2024.
• Asia Pacific is expected to grow at a notable CAGR 10% in the coming years.
• By type, the tetravalent segment held the biggest market share of 58% in 2024.
• By type, the trivalent segment is projected to grow at a significant rate during the forecast period.
• By target population, the infants and children (9 to 12 months) segment contributed the biggest market share of 68% in 2024.
• By target population, the adults segment is likely to grow at a notable CAGR between 2025 and 2034.
• By distribution channel, the vaccine centers and public health clinics segment held the biggest market share of held the biggest market share of 42% in 2024.
• By distribution channel, the pediatric and private healthcare clinics segment is expected to grow at a CAGR of 9.31% during the projection period.

Global Immunization Boost: How MMR Vaccines Are Making a Difference

Measles, mumps, and rubella are common infectious and communicable diseases. The measles, mumps, rubella vaccine market is witnessing consistent growth because of growing awareness among the people about the benefits of vaccinations. According to the World Health Organization (WHO), measles vaccination has prevented more than 60 million deaths from the year 2000 to 2023. The measles, mumps, and rubella (MMR) vaccine helps prevent the escalation of diseases, especially in children. The MMR vaccine provides protection against these infections, saving the individual from any serious complications.

Governments and other agencies are launching campaigns to spread awareness regarding infectious diseases, boosting the demand for MMR vaccines. Moreover, governments worldwide are launching immunization programs to address public health concerns. The ongoing active efforts have helped improve the vaccination rates, specifically in developing countries. Advancements in technology have significantly enhanced the capability of vaccine production, contributing to the growth of the market.

How is AI enhancing advancements in the Measles, Mumps, Rubella Vaccine Market?

Artificial Intelligence (AI) has been widely used in the development of vaccines in the last few years. In the development of measles, mumps, and rubella vaccines, AI helps accelerate the process of vaccine development along with speeding up research and development activities. AI and machine learning (ML) algorithms can quickly process and analyze large amounts of data from clinical trials. This data helps determine patterns and trends that were missed in the manual processes. AI reduces human errors and analyzes the data quicker to help speed up the vaccine development process. AI technology plays an important role in improving the efficacy and safety of vaccines. AI can predict the probable efficacy as well as safety of potential vaccines through analysis of the existing data. Moreover, AI algorithms analyze vast datasets to identify potential vaccine candidates and accelerate clinical trials.

• In March 2025, Dr. Monica Cojocaru, a professor in University of Guelph in Canada, utilized an AI-powered tool to track the hesitancy of measles vaccines.

Measles, Mumps, Rubella Vaccine Market Growth Factors

• The increasing awareness among the people about the measles outbreak and the importance of vaccination is boosting the growth of the market.
• The growing focus on vaccine security and improving distribution efficiency, especially after the COVID-19 pandemic, is propelling the market's growth.
• The rising research and development activities aimed at developing novel vaccines further boost the growth of the market.

Market Outlook

• Industry Growth Offerings- The MMR vaccine industry is growing due to increasing immunization campaigns, rising disease surveillance, and advancements in vaccine technology. Companies are focusing on improved formulations, wider production capacity, and global partnerships to enhance vaccine accessibility and support large-scale public health programs.
• Global Expansion- Global expansion of MMR vaccines is driven by widening immunization programs, stronger international collaborations, and improved vaccine supply chains. Manufacturers are increasing exports, entering new markets, and partnering with global health agencies to boost vaccination coverage, especially in developing regions.
• Startup ecosystem- The startup ecosystem is growing as emerging biotech firms focus on innovative delivery systems, improved vaccine stability, and low-cost formulations. Startups are partnering with governments and global health organizations to enhance accessibility, expand research, and strengthen immunization coverage in underserved regions.

Market Scope

Market Dynamics

Drivers

Government Initiatives

The rising government initiatives to spread awareness among the population about measles is a key factor driving the growth of the measles, mumps, rubella vaccine market. Governments across the world, along with health agencies like WHO, have mandated vaccination programs. The Expanded Program on Immunization (EPI), launched by the WHO, ensures access to life-saving vaccines for children across the globe. The rising government investment in the discovery and development of novel vaccines further drives the market's growth. Governments around the world are also launching various campaigns to spread awareness regarding life-saving vaccines, like measles, which have improved the rates of vaccination, especially in emerging countries. For instance, recently, the Indian Union Ministry of Health launched a National Zero Measles-Rubella Elimination campaign 2025-26. This campaign aims to achieve 100% immunization to save individuals from these infectious diseases in the country.

Restraint

Misinformation and Hesitation

Misinformation leads to vaccine hesitancy, limiting the growth of the measles, mumps, rubella vaccine market. There is a lot of false information about MMR vaccines. One such false claim is that the MMR vaccine can cause autism. It has raised a lot of questions in society about the possible side effects, safety, and even advantages of vaccinations. Recently, a study revealed that there has been a rise in the number of unvaccinated children in the U.S., which is one of the key reasons for outbreaks like measles. The spread of misinformation discourages people from taking vaccinations, affecting the growth of the market.

Opportunity

Technological Advancements

Ongoing technological advancements in vaccine development processes open up new opportunities for innovation and growth for the measles, mumps, rubella vaccine market. With advanced technologies, the process of vaccine development can be improved. Advanced technologies, like AI, help accelerate research and development activities, providing a broad scope for innovation and rapid vaccine development. Advanced technologies can achieve enhanced efficacy and safety of vaccines. Moreover, the healthcare sector is investing in innovative technologies, like digital health solutions, to improve vaccine delivery and track immunization records, which further propels the growth of the market in the coming years.

Segment Insights

Type Insights

The tetravalent segment led the measles, mumps, rubella vaccine market with the largest share in 2024. This is mainly due to the increased demand for comprehensive immunization that offers protection against multiple diseases in a single vaccine. Tetravalent vaccines combine measles, mumps, and rubella vaccines in a single dose, reducing the need for multiple vaccines. This convenience is particularly beneficial for children. It is also easier to administer a single dose to infants and children for a group of diseases to minimize their discomfort.

Meanwhile, the trivalent segment is projected to grow at a significant rate during the forecast period. The growth of the segment is attributed to the proven efficacy of trivalent vaccines in preventing measles, mumps, and rubella. Trivalent vaccines are gaining popularity because they contain antigens from three types of pathogens or strains, which protect from all these diseases. The rising awareness about the benefits of trivalent vaccines is likely to boost the growth of this segment.

Target Population Insights

The infants and children (9 to 12 months) segment dominated the measles, mumps, rubella vaccine market in 2024. This is mainly due to parents' heightened awareness about infant vaccination. Public health agencies, like the World Health Organization (WHO), and governments across the world have been making efforts to spread awareness and promote vaccines for children to prevent diseases. With continuous government efforts and investments in vaccination programs, especially in emerging countries, the demand for MMR vaccines has increased.

On the other hand, the adults segment is likely to grow at a notable rate during the forecast period. The evolving health policies for vaccine programs and the increasing awareness among the adult population about immunization are likely to drive the growth of this segment. Increased travel has increased the risk of exposure to these diseases for adults, boosting the demand for MMR vaccines. The rising immunization programs for adults, particularly those who missed vaccines in their childhood, further boost the growth of the segment.

Distribution Channel

The vaccine centers and public health clinics segment led the measles, mumps, rubella vaccine market in 2024. Public health facilities, like public vaccination clinics, are the major end-users of MMR vaccines. These facilities are often engaged in immunization programs and play a crucial role in areas where the population relies on public health services. Many governments prioritize MMR vaccination through public health programs, bolstering the segment's growth.

On the other hand, the pediatric and private healthcare clinics segment is expected to witness the fastest growth during the projection period. In the developed parts across the globe, private healthcare clinics play an important role in national immunization programs. These facilities offer the convenience and flexibility that appeals to people. The rising awareness among parents about the importance of timely vaccinations for children is likely to support the growth of the segment.

Regional Insights

U.S. Measles, Mumps, Rubella Vaccine Market Size and Growth 2025 to 2034

The U.S. measles, mumps, rubella vaccine market size is exhibited at USD 621.15 million in 2025 and is projected to be worth around USD 1319.10 million by 2034, growing at a CAGR of 8.71% from 2025 to 2034.

What Keep North America at the Forefront of the MMR Vaccine Industry?

North America dominated the measles, mumps, rubella vaccine market by holding the largest share in 2024. This is mainly due to the increased initiatives by public health clinics and governments to promote MMR vaccines. There is a strong emphasis on developing innovative vaccines. The heightened integration of advanced technologies in the healthcare sector as well as research and development activities further bolstered the market in the region.

The region is likely to sustain its position in the market. This is mainly due to the rising government investments in vaccine discovery and development. The U.S. plays a crucial part in the growth of the market. The country is home to well-established biotechnology companies and R&D institutes that invest in vaccine development. The regulatory support from the U.S. FDA and increasing approvals for MMR vaccines are major factors propelling the market's growth. In addition, heightened awareness about vaccinations supports the market's growth.

• In April 2025, four MMR vaccine clinics are underway in Provincetown, Massachusetts, U.S., to help anyone who is under-vaccinated, unvaccinated, or of unknown vaccine status, in order to ensure immunization in the region. This move is taken as a preventive action against the recent outspread of measles in the U.S.

Asia Pacific's MMR Vaccine Boom: What's Driving the Momentum?

Asia Pacific is expected to witness the fastest growth in the upcoming period. The increasing healthcare expenditure is a key factor driving the growth of the market. The region has a large and growing population, creating the need for MMR vaccines. The increased availability and accessibility to public health services further contribute to regional market growth. Governments of various Asian countries are making efforts to improve vaccination coverage through awareness campaigns and immunization programs. The region boasts leading vaccine manufacturing companies, including Serum Institute of India, which further support market growth.

Countries like China and India are expected to have a stronghold on the measles, mumps, rubella vaccine market in Asia Pacific. Various initiatives taken by governments to improve vaccination rates are expected to drive market growth. With a strong emphasis on preventative healthcare, the demand for MMR vaccines is rising. In addition, rising government support for vaccination and awareness campaigns fuel the growth of the market.

How Europe is Strengthening its Lead in Immunization Through MMR Vaccines

Europe is expected to show notable growth during the forecast period. The growth of the market in Europe can be attributed to the rising government programs offering comprehensive vaccination. With growing concerns about public health, there is a strong emphasis on immunization programs. For instance, The European Immunization Agenda 2030 (EIA2030) is a strategy and vision developed and adopted by all 53 member countries. This policy aims to achieve the full benefits of vaccinations in the region. The U.K. plays a major role in the market growth in Europe. High vaccination coverage rates and increased awareness among parents about infant vaccination drive the growth of the market. Data published by Public Health Scotland in June 2024 for 2023/2024 showed that 89.2% of children had both doses of the MMR vaccine by the age of five years.

What's Powering the Surge in the U.S. MMR Vaccine Market?

The U.S. market is expanding due to rising measles outbreaks, increasing public health awareness, and strong government-led immunization initiatives. High vaccination recommendations from the CDC, combined with school immunization requirements, continue to boost demand. Advancements in vaccine production, improved supply chain systems, and ongoing research into safer and more effective formulations further support market growth. Additionally, strong healthcare infrastructure ensures broad vaccine accessibility across the country.

Why is the Seeking a Renewed Rise in MMR Vaccine Demand?

China's market is growing as the country focuses on strengthening disease surveillance systems and upgrading its public health infrastructure. Increased monitoring of infectious diseases has highlighted the need for wider MMR immunization. Rising government spending on childhood healthcare, expansion of community health centers, and improved cold-chain logistics are boosting vaccine uptake. Additionally, China's biotechnology sector is advancing rapidly, enabling the development of enhanced MMR formulations and a stable supply.

What's Driving China's Rapid Expansion in the MMR Vaccine Market?

The UK market is expanding due to rising concerns over declining childhood vaccination rates, prompting stronger NHS-led catch-up campaigns and public health initiatives. Increased focus on preventing outbreaks, along with enhanced community outreach and digital reminders, is improving immunization uptake. The government is also investing in strengthening vaccine supply chains and expanding access through pharmacies and GP clinics. Growing awareness of preventable diseases further supports market growth.

Value Chain Analysis

• R&D
  R&D in the MMR vaccine market is driven by the growing incidence of measles, mumps, and rubella worldwide.
  Development of combination vaccines, such as tetravalent formulations, aims to improve cost-effectiveness and convenience.
  Efforts focus on increasing vaccination coverage, particularly among vulnerable populations and children.
  Key players: Merck & Co., GlaxoSmithKline (GSK), Pfizer, Sanofi, and Serum Institute of India.
• Clinical Trials and Regulatory Approvals
  Clinical trials for MMR vaccines are focused on testing new formulations and innovative delivery methods, such as microarray patches and high-speed injectors.
  Regulatory approvals are granted after thorough evaluation of efficacy and safety data from these trials.
  Key players: Merck & Co., GlaxoSmithKline (GSK), Pfizer, Sanofi, and Serum Institute of India.
• Distribution to Hospitals, Pharmacies
  The MMR vaccine market is distributed via hospitals, private clinics, government programs, and retail pharmacies.
  Hospitals and clinics serve as primary distribution channels due to trusted patient relationships.
  Retail pharmacies enhance accessibility and convenience for the general population.
  Key players: GlaxoSmithKline (GSK), Pfizer, Sanofi, and Serum Institute of India.

Key Players in Measles, Mumps, Rubella Vaccine Market and Their Offerings

• GSK (GlaxoSmithKline): GSK offers a strong vaccine portfolio, including pediatric and combination vaccines. The company focuses on large-scale immunization programs, advanced R&D, and global partnerships to expand access to MMR and related vaccines worldwide.
• Sanofi: Sanofi provides widely used pediatric and combination vaccines. The company emphasizes high-quality manufacturing, continuous vaccine innovation, and collaborations with global health agencies to improve vaccination coverage and strengthen disease-prevention efforts.
• Sinovac Biotech: Sinovac manufactures multiple pediatric vaccines, including MMR formulations. It focuses on affordable vaccine production, expansion into developing markets, and strengthening global immunization programs through efficient manufacturing and distribution networks.
• Merck & Co., Inc.: Merck is a key provider of MMR vaccines, supported by strong R&D and biotechnology expertise. The company develops high-efficacy vaccines and works closely with public health bodies to enhance global immunization rates.
• Serum Institute of India Pvt. Ltd.: Serum Institute produces cost-effective, high-volume MMR vaccines. As one of the world's largest vaccine manufacturers, it supports global immunization initiatives and expands access across low- and middle-income countries.
• Biological E. Limited: Biological E manufactures MMR and other pediatric vaccines with a focus on affordability and accessibility. The company strengthens global vaccine supply through large-scale production, strategic partnerships, and ongoing vaccine development initiatives.

Segments Covered in the Report

By Type

• Monovalent
• Trivalent (combined MMR)
• Tetravalent

By Targeted Population

• Infants and Children (9 to 12 months)
• Adults

By Distribution Channel

• Hospitals and Healthcare Institutions
• Vaccine Centers and Public Health Clinics
• Pediatric and Private Healthcare Clinics

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa